Ironwood Pharmaceuticals (IRWD) EPS (Basic) (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EPS (Basic) across 17 years of filings, most recently posting $0.25 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $0.25, up 208.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.64 (up 404.76% YoY), and the FY2025 annual result was $0.15, up 1400.0% from the prior year.
• EPS (Basic) came in at $0.25 for Q1 2026 at Ironwood Pharmaceuticals, up from -$0.01 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.33 in Q3 2022 to a low of -$6.84 in Q2 2023.
• The 5-year median for EPS (Basic) is $0.1 (2023), against an average of -$0.29.
• Across the five-year window, EPS (Basic) slumped 2950.0% in 2023 and jumped 1600.0% in 2025, its largest moves.
• Ironwood Pharmaceuticals' EPS (Basic) stood at $0.32 in 2022, then sank by 103.12% to -$0.01 in 2023, then soared by 200.0% to $0.01 in 2024, then slumped by 200.0% to -$0.01 in 2025, then soared by 2600.0% to $0.25 in 2026.
• The last three EPS (Basic) figures came in at $0.25 (Q1 2026), -$0.01 (Q4 2025), and $0.25 (Q3 2025), per Business Quant data.